Analysts expect over 2023 growing sales Biocartis

Next Monday the French company Biocartis will publish its past quarters results. Over the current book year the total revenu from the company based in will be 58 million euros (consensus estimates). This is slightly more than 2022's revenue of 57.48 million euros.

Historical revenues and results Biocartis plus estimates 2023

Apple store Amsterdam © Biocartis

The analysts expect for 2023 a net loss of 47 million euros. For this year the consensus of the result per share is a loss of 32 cent. Based on this the price/earnings-ratio is -0.91.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals an attractive 3.55 percent.

Recent target prices around 1 euros

DeGroof Petercam, KBC Securities and KBC Securities recently provided recommendations for the stock.

Based on the current number of outstanding shares Biocartis 's market capitalization 19.13 million euros.

On Tuesday the stock closed at 0.29 euros.

Historical stock prices Biocartis

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.